Vitalii Yu. Roshchin

Vitalii Yu. Roshchin

Auto-generated profile, based on publicly available information

Vitalii Yu. Roshchin

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2022 in Cold Spring Harbor Molecular Case Studies
Verified
Journal Article
Open access
PDF file
APAgnesa V. Panferova
Agnesa V. Panferova
KSKseniya Yu. Sinichenkova
Kseniya Yu. Sinichenkova
MJMeriam Abu Jabal
Meriam Abu Jabal
NUNatalia Usman
Natalia Usman
ASAnastasya S. Sharlai
Anastasya S. Sharlai
ADAlexander E. Druy
Alexander E. Druy
The World Health Organization (WHO) Classification of Tumors of Soft Tissue and Bone subdivides rhabdomyosarcomas (RMSs) into alveolar, embryonal, pleomorphic, and spindle cell RMSs. Advances in molecular genetic diagnostics have made it possible to identify new RMS subgroups within traditional morphological entities. One of these subgroups comprises rare tumors characterized by epithelioid and spindle cell morphology, a highly aggressive clinical course with pronounced tendency to intraosseous growth, and the presence of pathognomonic recurring genetic aberrations—chimeric genes/transcripts EWSR1::TFCP2, FUS::TFCP2, or MEIS1::NCOA2. Starting from 2018, only 26 reported cases of RMS have been assigned to this subgroup. The rarity of such tumors hampers their correct diagnostics for both anatomic pathologists and molecular oncologists. Here, we describe a clinical case of intraosseous spindle cell RMSs expressing the EWSR1::TFCP2 fusion gene, encountered for the first time in our practice, in a 16-yr-old female patient presenting with mandibular lesion. The diagnostic process took considerable time and involved RNA sequencing—a high-throughput method of molecular genetic research. The tumor was extremely aggressive, showing resistance to polychemotherapy, radiation therapy, and crizotinib-targeted therapy, with the fatal outcome.

12 May 2023 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
TST. V. Shamanskaya
T. V. Shamanskaya
SVS. R. Varfolomeeva
S. R. Varfolomeeva
DKDenis Kachanov
Denis Kachanov
RMR. A. Moiseenko
R. A. Moiseenko
MTM. V. Teleshova
M. V. Teleshova
ВРВ. Ю. Рощин
В. Ю. Рощин
Treatment of patients with high-risk neuroblastoma (NB) is a complex challenge, and it is based on response to certain elements of therapy. The development and introduction of new treatment approaches, such as GD2-targeted immunotherapy (IT), leads to improved survival in this cohort of patients. The aim of the study was to retrospectively assess the effectiveness of therapy in patients with high-risk NB before the introduction of IT into clinical practice. We retrospectively analyzed the data of 151 NB patients stratified into a high-risk group who had received treatment in accordance with the modified NB2004 protocol of the German Society for Pediatric Oncology and Hematology (GPOH) at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology from 01.2012 to 12.2017. This study was approved by the Independent Ethics Committee and the Academic Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. All the study subjects (or their legal representatives) signed a voluntary informed consent form indicating their agreement to treatment and use of their data for research purposes. Overall survival (OS), event-free survival (EFS), and risk factors were analyzed in the patients with high-risk NB including those who had completed multimodal therapy with autologous hematopoietic stem cell transplantation and post-consolidation therapy with isotretinoin and had achieved a satisfactory response to induction therapy (complete response (CR), very good partial response (VGPR), partial response (PR)) (population of special interest). The main unfavorable prognostic clinical and molecular genetic factors affecting survival in the high-risk NB patients were older age, MYCN gene amplification, and stage 4 of the disease. The use of the modified GPOH NB2004 protocol resulted in a satisfactory response (CR/VGPR/PR) to the induction therapy in most patients: 124/151 (82.1 %). Surgery (other than primary tumor biopsy) led to improved survival, with no statistical difference between macroscopic radical surgery and macroscopic residual tumor. At the same time, radiation therapy (RT), as the second element of local control, had a significant impact on EFS in the group of the patients with stage 4 disease: the 3-year EFS was 39.4 % (95 % confidence interval (CI) 23.1–55.4) in the patients with RT versus 25.7 % (95 % CI 17.5–34.7) in the patients without RT (p = 0.0295). The introduction of a new high-dose TreoMel chemotherapy regimen did not result in worse survival rates but led to a decrease in transplant-related toxicity. The 5-year OS and 5-year EFS were 49.4 % (95 % CI 40.9–57.3 %) and 33.3 % (95 % CI 25.9–40.9) respectively for all the study subjects, and 81.6 % (95 % CI 70.3–88.9) and 55.1 % (95 % CI 43.1–65.5) respectively for the patients from the population of special interest. The analysis of the results of therapy in the high-risk NB patients who had received treatment at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, yielded results comparable to those of the original GPOH NB2004 protocol. The patients with CR/VGPR/PR to the induction therapy who had completed the protocol treatment with autologous hematopoietic stem cell transplantation and isotretinoin post-consolidation therapy demonstrated higher 5-year EFS rates. However, there remains a need to develop more effective treatment regimens for high-risk NB.

21 December 2020 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
SBS. B. Babakhanova
S. B. Babakhanova
DKDenis Kachanov
Denis Kachanov
ASA. P. Shcherbakov
A. P. Shcherbakov
VRV. Yu. Roshchin
V. Yu. Roshchin
ADAlexander E. Druy
Alexander E. Druy
ВРВ. Ю. Рощин
В. Ю. Рощин
Ganglioneuroma (GN) represents a mature, well-differentiated tumor arising from the sympathetic nervous system. Mostly developing de novo, GN can appear during the treatment course of poorly differentiated or undifferentiated tumors of the sympathetic nervous system, such as neuroblastoma, or as a result of their spontaneous maturation. In this article we report three clinical cases of spontaneous and induced maturation of neuroblastoma (primary tumor and metastatic lesion) to GN. Histological verification of long-lasting stable or progressing residual tumor mases in patients with neuroblastoma stratified to the observation group plays a pivotal role as it may significantly affect the treatment course. The patients' parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.

4 July 2020 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
ASAmina Suleymanova
Amina Suleymanova
DKDenis Kachanov
Denis Kachanov
EIEvgeny N. Imyanitov
Evgeny N. Imyanitov
VRV. Yu. Roshchin
V. Yu. Roshchin
TST. V. Shamanskaya
T. V. Shamanskaya
ВРВ. Ю. Рощин
В. Ю. Рощин
Inflammatory myofibroblastic tumor (IMT) is a rare type of neoplasm with undetermined biological potential. IMT can occur in both childhood and adulthood. The standard of therapy is radical surgical treatment, but for patients with inoperable/recurrent or metastatic forms of IMT, therapeutic options are very limited. This literature review describes specific clinical, morphological and biological characteristics of this neoplasm, provides modern approaches to the diagnosis and treatment of IMT.

28 March 2020 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
AKA. Kailash
A. Kailash
EKE. D. Kireeva
E. D. Kireeva
IVI. S. Vdovina
I. S. Vdovina
M. Ya. YadgarovM. Ya. Yadgarov
M. Ya. Yadgarov
TST. V. Shamanskaya
T. V. Shamanskaya
ВРВ. Ю. Рощин
В. Ю. Рощин
¹²³I-metaiodobenzylguanidine (¹²³I-MIBG) scintigraphy is widely used for the detection and staging of neuroblastoma. Risk-adapted treatment in patients with neuroblastic tumors is based on many clinical and genetic factors including histopathology. Purpose: non-invasive prediction of an unfavorable histological variant in patients with neuroblastic tumors using quantitative assessment of ¹²³I-MIBG uptake. This study was approved by the Independent Ethical Committee and the Academic Council of Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation. 96 patients were included in this retrospective study. ¹²³I-MIBG-scintigraphy including whole body planner images and SPECT/CT were performed for all patients before any type of treatment. Semiquantitative and quantitative assessment of ¹²³I-MIBG uptake were calculated and analyzed. Out of 96 patients: 54 with neuroblastoma (NB), 28 with ganglioneuroblastoma (GNB) and 14 with ganglioneuroma (GN). The average values of TLCRR and SUVmax for NB were 5.67 and 7.5, for GNB – 2.58 and 3.1 and for GN – 1.48 and 1.85, respectively. A centile analysis was carried out for all groups. SPECT/CT in combination with modern software allows semiquantitative and quantitative assessment of ¹²³I-MIBG uptake in neuroblastic tumor. The TLCRR and SUVmax can be used separately as well as in combination with NSE for prediction of histological variant.

21 December 2020 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
ASA. S. Sharlai
A. S. Sharlai
GBG. K. Botiralieva
G. K. Botiralieva
ADAlexander E. Druy
Alexander E. Druy
VRV. Yu. Roshchin
V. Yu. Roshchin
DKD. M. Konovalov
D. M. Konovalov
ВРВ. Ю. Рощин
В. Ю. Рощин
Rhabdomyosarcomas (RMS) are group of soft tissue malignant tumours predominantly childhood. Alveolar rhabdomyosarcoma (aRMS) is the second most common variant of RMS. The majority of aRMSs display a translocations of FOXO1 gene. Such tumours are aggressive, metastasize early and are associated with a worse prognosis for the patient. However, some aRMS cases are rhabdomyosarcomas without classic chromosomal rearrangements. These tumors also have alveolar morphology, but neoplastic cells lack the FOXO1 gene translocation. Such fusion-negative round-cell RMSs behave clinically differently and have a better prognosis. The aim of the present study was to assess the prevalence of FOXO1 gene rearrangements in the group of round cell rhabdomyosarcomas with alveolar morphology. This study is supported by the Independent Ethics Committee and approved by the Academic Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The study group consisted of 250 formalin-fixed paraffin-embedded samples from patients with RMS. The cytogenetic study was performed by fluorescence in situ hybridization with a locus-specific identifier (LSI) for FOXO1 (13q14). The PAX3-FOXO1 (COSF247) and PAX7-FOXO1 (COSF287) fusion transcripts was detected by RT-PCR. In the study group 1 (аRMS), the rearrangement of PAX3/7-FOXO1 was detected in 44% of cases, in 32% of cases was detected a combined rearrangement with amplification of the 3' FOXO1. In one case, the amplification of the 3' end of the FOXO1 gene was detected without rearrangement; this sample was sent for additional PCR study, as a result of which the chimeric PAX3-FOXO1 transcript was detected. In 22% cases cytogenetic abnormalities were not found. has not been identified. In group 2 (embryonal RMS) we did not detect translocation. The group of round-cell PMCs is heterogeneous and is represented by three variants of genetic events that determine the disease prognosis. At the same time, FOXO1 gene abnormalities are not found in the RMS group with non-alveolar morphology.